Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Grootendorst

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|April 4, 2001
Censoring in statistical models of health status: what happens when one can do better than '1'P Grootendorst
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|August 27, 1999
Evaluating the impact of reference-based pricingP Grootendorst, A Holbrook
Pharmacoepidemiology and Drug Safety|November 26, 2008
Proportion of osteoporotic post-menopausal women at increased risk for upper GI adverse events associated with bisphosphonate therapyM A Levine, P Grootendorst
Medical Care|March 16, 2000
Health Utilities Index Mark 3: evidence of construct validity for stroke and arthritis in a population health surveyP Grootendorst, D Feeny, W Furlong
The Canadian Journal of Cardiology|July 1, 1997
Reference-based pricing (RBP) of prescription drugsA Holbrook, B O'Brien, P Grootendorst
Statistics in Medicine|September 12, 2007
Use of instrumental variables in the analysis of generalized linear models in the presence of unmeasured confounding with applications to epidemiological researchK M Johnston, P Gustafson, A R Levy, et al.
Health Policy (Amsterdam, Netherlands)|February 13, 2001
On the evaluation of drug benefits policy changes with longitudinal claims data: the policy maker's versus the clinician's perspectiveS Schneeweiss, M Maclure, A M Walker, et al.
Clinical and Investigative Medicine. Medecine Clinique Et Experimentale|December 1, 1995
Cost analysis of dialysis treatments for end-stage renal disease (ESRD)R Goeree, J Manalich, P Grootendorst, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|May 16, 2022
Fracture definitions in observational osteoporosis drug effects studies that leverage healthcare administrative (claims) data: a scoping reviewN Konstantelos, A M Rzepka, A M Burden, et al.
Canadian Journal of Public Health = Revue Canadienne De Sante Publique|April 20, 2006
Impact of antibiotic administrative restrictions on trends in antibiotic resistanceD A Marshall, A McGeer, J Gough, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|April 4, 2001
Censoring in statistical models of health status: what happens when one can do better than '1'P Grootendorst
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|August 27, 1999
Evaluating the impact of reference-based pricingP Grootendorst, A Holbrook
Pharmacoepidemiology and Drug Safety|November 26, 2008
Proportion of osteoporotic post-menopausal women at increased risk for upper GI adverse events associated with bisphosphonate therapyM A Levine, P Grootendorst
Medical Care|March 16, 2000
Health Utilities Index Mark 3: evidence of construct validity for stroke and arthritis in a population health surveyP Grootendorst, D Feeny, W Furlong
The Canadian Journal of Cardiology|July 1, 1997
Reference-based pricing (RBP) of prescription drugsA Holbrook, B O'Brien, P Grootendorst
Statistics in Medicine|September 12, 2007
Use of instrumental variables in the analysis of generalized linear models in the presence of unmeasured confounding with applications to epidemiological researchK M Johnston, P Gustafson, A R Levy, et al.
Health Policy (Amsterdam, Netherlands)|February 13, 2001
On the evaluation of drug benefits policy changes with longitudinal claims data: the policy maker's versus the clinician's perspectiveS Schneeweiss, M Maclure, A M Walker, et al.
Clinical and Investigative Medicine. Medecine Clinique Et Experimentale|December 1, 1995
Cost analysis of dialysis treatments for end-stage renal disease (ESRD)R Goeree, J Manalich, P Grootendorst, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|May 16, 2022
Fracture definitions in observational osteoporosis drug effects studies that leverage healthcare administrative (claims) data: a scoping reviewN Konstantelos, A M Rzepka, A M Burden, et al.
Canadian Journal of Public Health = Revue Canadienne De Sante Publique|April 20, 2006
Impact of antibiotic administrative restrictions on trends in antibiotic resistanceD A Marshall, A McGeer, J Gough, et al.
Pageof 2